Shin, H., Moon, S. H., Lee, S. J., Ahn, Y. (2025). A phase 1 trial of APX-343A, NOX inhibitor targeting CAF-mediated immunosuppression, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2697